Sir, Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment
The antivascular endothelial growth factor aptamer pegaptanib may induce short-term regression of retinal neovascularisation secondary to diabetes. 1 We present two diabetic patients who underwent intravitreal pegaptanib for persistent retinal neovascularisation and developed the progression of a previously stable tractional retinal detachment (TRD).
Case reports

Case 1
A 26-year-old woman with severe proliferative diabetic retinopathy underwent extensive scatter laser photocoagulation (PRP) leading to the regression of neovascularisation and a localised right inferotemporal TRD.
After 6 months, the TRD appeared unchanged, but fresh vitreous and preretinal haemorrhages were observed. Informed consent was obtained for intravitreal pegaptanib (0.3 mg/0.9 ml).
Ten days after injection, the TRD appeared stable (Figure 1) . By 5 weeks, TRD progression had resulted in macular elevation and reduced visual acuity from 6/12 to 6/36 (Figure 2) .
The patient underwent vitrectomy, delamination, endolaser, and sulphur hexafluoride gas with minimal intraoperative haemorrhage. After 2 months, the visual acuity was 6/12.
Case 2
A 48-year-old woman with proliferative diabetic retinopathy underwent extensive PRP and developed TRD associated with regressed inferotemporal neovascularisation. After 8 months, active neovascularisation recurred although the TRD remained unchanged (Figure 3a and b).
Informed consent was obtained for intravitreal pegaptanib (0.3 mg/0.9 ml). Three weeks later, although neovascularisation and preretinal haemorrhage had improved, the TRD had progressed and visual acuity reduced from 6/36 to counting fingers (Figure 4a and b) . The patient underwent right vitrectomy, delamination, and octafluoropropane gas. Minimal intraoperative haemorrhage permitted a low infusion pressure during surgery. After 6 weeks, the visual acuity was 6/12.
Comment
The preexisting TRD had remained stable for 6 months and 8 months in cases 1 and 2, respectively before progressing within the weeks of intravitreal pegaptanib. Reports exist of TRD progression following intravitreal bevacizumab in proliferative diabetic retinopathy. 2, 3 However, there are currently no reports in the literature associating intravitreal pegaptanib with TRD progression.
Intravitreal pegaptanib did, however, result in less intraoperative haemorrhage than expected. This reduced the risk of further circulatory compromise in a diabetic due to prolonged elevated intraocular pressure while attempting to achieve haemostasis.
We feel that the rapid progression of the TRD in these patients is largely attributable to the pegaptanib. Although intravitreal pegaptanib may potentially be a useful management tool in severe proliferative diabetic retinopathy, in patients with preexisting TRD, we would advise caution and careful monitoring following its use. 
